An Effective N6-methyladenosine-related Long Non-coding RNA Prognostic Signature for Predicting the Prognosis of Patients with Bladder Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Nov 22

PMID 34802433

Citations 12

Authors

Tianming Ma

Xiaonan Wang

Lingfeng Meng

Xiaodong Liu

Jiawen Wang

Wei Zhang

Zijian Tian

Yaoguang Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Bladder cancer (BLCA) typically has a poor prognosis due to high relapse and metastasis rates. A growing body of evidence indicates that N6-methyladenosine (m6A) and long non-coding RNAs (lncRNAs) play crucial roles in the progression of BLCA and the treatment response of patients with BLCA. Therefore, we conducted a comprehensive RNA-seq analysis of BLCA using data from The Cancer Genome Atlas (TCGA) to establish an m6A-related lncRNA prognostic signature (m6A-RLPS) for BLCA.

Methods: Consensus clustering analysis was used to investigate clusters of BLCA patients with varying prognoses. The least absolute shrinkage and selection operator Cox regression were used to develop the m6A-RLPS. The ESTIMATE and CIBERSORT algorithms were used to evaluate the immune composition.

Results: A total of 745 m6A-related lncRNAs were identified using Pearson correlation analysis (|R| > 0.4, p < 0.001). Fifty-one prognostic m6A-related lncRNAs were screened using univariate Cox regression analysis. Through consensus clustering analysis, patients were divided into two clusters (clusters 1 and 2) with different overall survival rates and tumor stages based on the differential expression of the lncRNAs. Enrichment analysis demonstrated that terms related to tumor biological processes and immune-related activities were increased in patient cluster 2, which was more likely to exhibit low survival rates. Nine m6A-related prognostic lncRNAs were finally determined and subsequently used to construct the m6A-RLPS, which was verified to be an independent predictor of prognosis using univariate and multivariate Cox regression analyses. Further, a nomogram based on age, tumor stage, and the m6A-RLPS was generated and showed high accuracy and reliability with respect to predicting the survival outcomes of BLCA patients. The prognostic signature was found to be strongly correlated to tumor-infiltrating immune cells and immune checkpoint expression.

Conclusions: We established a novel m6A-RLPS with a favorable prognostic value for patients with BLCA. We believe that this prognostic signature can provide new insights into the tumorigenesis of BLCA and predict the treatment response in patients with BLCA.

Citing Articles

Yang F, Ren Y, Qi D, Liu X, Xie J J Cancer. 2025; 16(2):460-469.

PMID: 39744498 PMC: 11685695. DOI: 10.7150/jca.101823.

Knowledge mapping and current trends of m6A methylation in the field of cancer.

Zhu C, Yang J, Zhang C, Wang Y, Wang J Heliyon. 2024; 10(4):e26262.

PMID: 38434062 PMC: 10906179. DOI: 10.1016/j.heliyon.2024.e26262.

RNA N-methyladenosine modifications in urological cancers: from mechanism to application.

Yang L, Ying J, Tao Q, Zhang Q Nat Rev Urol. 2024; 21(8):460-476.

PMID: 38347160 DOI: 10.1038/s41585-023-00851-x.

Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.

Han Y, Kim U, Jung K, Lee J, Lee K, Shin S Cancer Metab. 2023; 11(1):23.

PMID: 38053135 PMC: 10696702. DOI: 10.1186/s40170-023-00324-0.

Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.

Sanya D, Onesime D Hum Cell. 2023; 36(4):1343-1372.

PMID: 37209205 DOI: 10.1007/s13577-023-00915-5.

References

Rui X, Wang L, Pan H, Gu T, Shao S, Leng J . LncRNA GAS6-AS2 promotes bladder cancer proliferation and metastasis via GAS6-AS2/miR-298/CDK9 axis. J Cell Mol Med. 2018; 23(2):865-876. PMC: 6349183. DOI: 10.1111/jcmm.13986. View

Zhu S, Yu W, Yang X, Wu C, Cheng F . Traditional Classification and Novel Subtyping Systems for Bladder Cancer. Front Oncol. 2020; 10:102. PMC: 7025453. DOI: 10.3389/fonc.2020.00102. View

Martens-Uzunova E, Bottcher R, Croce C, Jenster G, Visakorpi T, Calin G . Long noncoding RNA in prostate, bladder, and kidney cancer. Eur Urol. 2013; 65(6):1140-51. DOI: 10.1016/j.eururo.2013.12.003. View

Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M . The mA methyltransferase METTL3 promotes bladder cancer progression via AFF4/NF-κB/MYC signaling network. Oncogene. 2019; 38(19):3667-3680. DOI: 10.1038/s41388-019-0683-z. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View

Deng X, Su R, Weng H, Huang H, Li Z, Chen J . RNA N-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018; 28(5):507-517. PMC: 5951805. DOI: 10.1038/s41422-018-0034-6. View

Zhang X, Liu H, Chen S . Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations. Cancers (Basel). 2020; 12(5). PMC: 7281179. DOI: 10.3390/cancers12051245. View

Denaro N, Merlano M, Lo Nigro C . Long noncoding RNAs as regulators of cancer immunity. Mol Oncol. 2018; 13(1):61-73. PMC: 6322193. DOI: 10.1002/1878-0261.12413. View

Albini A, Bruno A, Noonan D, Mortara L . Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Front Immunol. 2018; 9:527. PMC: 5895776. DOI: 10.3389/fimmu.2018.00527. View

10.

Han D, Liu J, Chen C, Dong L, Liu Y, Chang R . Anti-tumour immunity controlled through mRNA mA methylation and YTHDF1 in dendritic cells. Nature. 2019; 566(7743):270-274. PMC: 6522227. DOI: 10.1038/s41586-019-0916-x. View

11.

Chen M, Wei L, Law C, Tsang F, Shen J, Cheng C . RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. Hepatology. 2017; 67(6):2254-2270. DOI: 10.1002/hep.29683. View

12.

Cheng J, Li D, Lv M, Pei Y, Zhang X, Li L . LncRNA KCNQ1OT1 regulates the invasion and migration of hepatocellular carcinoma by acting on S1PR1 through miR-149. Cancer Gene Ther. 2020; 28(7-8):850-863. PMC: 8370874. DOI: 10.1038/s41417-020-0203-x. View

13.

Carosella E, Ploussard G, LeMaoult J, Desgrandchamps F . A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G. Eur Urol. 2015; 68(2):267-79. DOI: 10.1016/j.eururo.2015.02.032. View

14.

Zuo X, Chen Z, Gao W, Zhang Y, Wang J, Wang J . M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. J Hematol Oncol. 2020; 13(1):5. PMC: 6951025. DOI: 10.1186/s13045-019-0839-x. View

15.

Li H, Tong J, Zhu S, Batista P, Duffy E, Zhao J . mA mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways. Nature. 2017; 548(7667):338-342. PMC: 5729908. DOI: 10.1038/nature23450. View

16.

Wang J, Zhang H, Situ J, Li M, Sun H . KCNQ1OT1 aggravates cell proliferation and migration in bladder cancer through modulating miR-145-5p/PCBP2 axis. Cancer Cell Int. 2019; 19:325. PMC: 6889643. DOI: 10.1186/s12935-019-1039-z. View

17.

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

18.

Chen M, Nie Z, Wen X, Gao Y, Cao H, Zhang S . m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer. Biosci Rep. 2019; 39(12). PMC: 6923333. DOI: 10.1042/BSR20192892. View

19.

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

20.

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View